Investor Overview

$0.22 - 0.00 (0.945%)
Data as of 09/28/16 at 4:02 PM ET
Minimum 20 minute delay
High 0.23
Low 0.22
Volume 701,627

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and SupinoxinTM (RX-5902) and a robust pipeline of preclinical compounds to treat multiple types of cancer.

©2016 by Rexahn Pharmaceuticals, Inc. All rights reserved
Rexahn Pharmaceuticals, Inc. - 15245 Shady Grove Road, Suite 455 - Rockville, MD 20850

Terms of Use
Privacy Policy